INTRODUCTION: Preclinical assessment of the heart rate corrected QT interval (QTc) is an important component of the cardiovascular safety evaluation in drug discovery. Here we aimed to quantify the translational relationship between QTc prolongation and shortening in the conscious telemetered dog and humans by a retrospective pharmacokinetic-pharmacodynamic (PKPD) analysis. METHODS: QTc effects of 2 proprietary compounds and 2 reference drugs (moxifloxacin and dofetilide) were quantified in conscious dogs and healthy volunteers via a linear and Emax pharmacokinetic-pharmacodynamic models. The translational relationship was quantified by correlating the QTc response from dog and human at matching free drug concentrations. RESULTS: A consistent translational relationship was found at low delta-QTc intervals indicating that a QTc change of 2.5-8 ms in dog would correspond to a 10 ms change in human. DISCUSSION: The translational relationship developed here can be used to predict the QTc liability in human using preclinical dog data. It could therefore help protect the health of human volunteers, for example by appropriate clinical study design and dose selection, as well as improve future decision-making and help reduce compound attrition due to changes in QT interval.
INTRODUCTION: Preclinical assessment of the heart rate corrected QT interval (QTc) is an important component of the cardiovascular safety evaluation in drug discovery. Here we aimed to quantify the translational relationship between QTc prolongation and shortening in the conscious telemetered dog and humans by a retrospective pharmacokinetic-pharmacodynamic (PKPD) analysis. METHODS:QTc effects of 2 proprietary compounds and 2 reference drugs (moxifloxacin and dofetilide) were quantified in conscious dogs and healthy volunteers via a linear and Emax pharmacokinetic-pharmacodynamic models. The translational relationship was quantified by correlating the QTc response from dog and human at matching free drug concentrations. RESULTS: A consistent translational relationship was found at low delta-QTc intervals indicating that a QTc change of 2.5-8 ms in dog would correspond to a 10 ms change in human. DISCUSSION: The translational relationship developed here can be used to predict the QTc liability in human using preclinical dog data. It could therefore help protect the health of human volunteers, for example by appropriate clinical study design and dose selection, as well as improve future decision-making and help reduce compound attrition due to changes in QT interval.
Authors: S Y A Cheung; J Parkinson; U Wählby-Hamrén; C D Dota; Å M Kragh; L Bergenholm; T Vik; T Collins; C Arfvidsson; C E Pollard; H K Tomkinson; B Hamrén Journal: J Pharmacokinet Pharmacodyn Date: 2018-05-07 Impact factor: 2.745
Authors: Raja Venkatasubramanian; Teresa A Collins; Lawrence J Lesko; Jerome T Mettetal; Mirjam N Trame Journal: Br J Pharmacol Date: 2020-06-18 Impact factor: 8.739
Authors: V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf Journal: Br J Pharmacol Date: 2015-07-21 Impact factor: 8.739
Authors: Eleonora Marostica; Karel Van Ammel; Ard Teisman; Koen Boussery; Jan Van Bocxlaer; Filip De Ridder; David Gallacher; An Vermeulen Journal: J Pharmacokinet Pharmacodyn Date: 2015-08-11 Impact factor: 2.745
Authors: Vincent F S Dubois; Giovanni Smania; Huixin Yu; Ramona Graf; Anne S Y Chain; Meindert Danhof; Oscar Della Pasqua Journal: Br J Clin Pharmacol Date: 2016-10-29 Impact factor: 4.335
Authors: Eleonora Marostica; Karel Van Ammel; Ard Teisman; David Gallacher; Jan Van Bocxlaer; Filip De Ridder; Koen Boussery; An Vermeulen Journal: AAPS J Date: 2016-04-26 Impact factor: 4.009
Authors: T A Collins; L Bergenholm; T Abdulla; Jwt Yates; N Evans; M J Chappell; J T Mettetal Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-03-11